Solid Biosciences Inc. — 2019 Form 10-K Summary
Reporting period: Fiscal year ended December 31, 2019. This is an annual filing, not a standalone fourth-quarter report; quarterly figures are included where available. The filing was signed March 12, 2020.
Business context
Solid Biosciences is a clinical-stage biotechnology company focused on Duchenne muscular dystrophy (DMD). Its lead candidate, SGT-001, is an AAV9 gene-transfer therapy intended to produce microdystrophin. The Phase I/II IGNITE DMD trial was on FDA clinical hold at year-end following a serious adverse event. The company had no approved products and generated no revenue.
Financial performance and liquidity
| Metric | 2019 | 2018 |
|---|---|---|
| Revenue | $0 | $0 |
| Research and development expense | $94.7 million | $58.0 million |
| General and administrative expense | $24.6 million | $17.7 million |
| Total operating expenses / operating loss | $119.3 million | $75.7 million |
| Net loss | $117.2 million | $74.8 million |
| Basic and diluted loss per share | $2.91 | $2.25 |
| Cash used in operating activities | $92.7 million | $70.2 million |
With no revenue, gross margin and operating margin are not meaningful. Losses have increased as development spending expanded. SGT-001 R&D expense rose $16.2 million, primarily from clinical development and manufacturing activity and $3.0 million in contract cancellation fees. Higher personnel, facility and external costs also contributed to increased R&D spending.
At December 31, 2019, cash, cash equivalents and available-for-sale securities totaled $83.5 million, down from $122.5 million. Working capital was $68.0 million, versus $116.2 million. Total assets were $103.5 million and total liabilities were $23.4 million. The company reported no debt outstanding; it had $0.9 million of finance-lease liabilities and $6.2 million of operating-lease liabilities.
Cash used in investing activities was $24.5 million of net cash provided, mainly reflecting net sales and maturities of securities; financing activities provided $57.9 million, principally from the July 2019 private placement. The placement generated $60.0 million gross proceeds from common shares and pre-funded warrants, or $57.9 million net.
Fourth-quarter 2019 operating expenses were $32.3 million and net loss was $31.9 million, compared with $22.4 million and $21.9 million, respectively, in fourth-quarter 2018. Fourth-quarter 2019 loss per share was $0.67, compared with $0.63.
Material changes and management outlook
- Annual net loss increased by $42.4 million year over year; operating cash use increased by $22.5 million.
- Management estimated year-end resources would fund operating expenses and capital requirements into 2021, but cautioned that the estimate depended on assumptions and resources could be used sooner. The auditor and management identified substantial doubt about the company’s ability to continue as a going concern within twelve months of issuance, given recurring losses, operating cash outflows and the need for additional financing.
- In January 2020, after year-end, the company announced a workforce reduction of approximately 30% to one-third and a narrower focus on SGT-001. It estimated about $2.1 million in restructuring costs, substantially to be paid in 2020, and expected lower 2020 R&D expense.
- The company said it may consider a company-owned GMP manufacturing facility after obtaining further trial data; estimated capital needs were $60 million to $75 million. This was a possibility, not a committed project.
- The filing reported that the 2019 clinical hold followed a drug-related serious adverse event in the third patient treated at 2E14 vg/kg: complement activation, thrombocytopenia, reduced red blood cell count, acute kidney injury and cardiopulmonary insufficiency. The event had resolved by December 2019. The FDA hold remained in place at year-end, and no timing for resolution was provided.
- December 2019 preliminary biopsy data for two patients at the higher dose showed microdystrophin expression by western blot of near the assay’s 5% quantification level for one patient (one replicate 5.5%) and 17.5% of normal control for the other. The filing separately reports March 2020 data for a third patient—after the reporting period—including 8% of normal control by western blot.
Risks, contingencies and unusual items
- Clinical development and the future of SGT-001 depend on FDA resolution of the clinical hold; safety findings could require additional studies, protocol changes, delay or termination.
- The company has no product revenue, expects continuing losses and states it will need additional funding. Financing may not be available on acceptable terms and could dilute shareholders or require concessions of rights.
- Manufacturing remains dependent on third parties; the company disclosed variability in manufacturing-run success and yield, alongside the need to scale and demonstrate consistent supply.
- Other programs, including anti-LTBP4 and the Solid Suit, had been materially curtailed to prioritize SGT-001.
- The filing lists $11.9 million of operating-lease, finance-lease and unconditional purchase commitments at year-end, excluding contingent license milestones and cancelable ordinary-course service contracts.
- A putative securities class action connected with the 2018 IPO was voluntarily dismissed without prejudice in June 2019. The filing reports no other material legal claims as of year-end.
- Management reported that previously identified material weaknesses in internal control over financial reporting were remediated by December 31, 2019; disclosure controls and internal control over financial reporting were assessed as effective. The auditor did not provide an internal-controls attestation.
Most important facts for investors to verify
- Current status and terms for lifting the FDA clinical hold, including any additional safety requirements and trial restart plans.
- Updated cash, cash burn and financing needs against the stated “into 2021” runway, including the effects of restructuring and any new clinical work.
- Whether subsequent SGT-001 clinical data support meaningful functional benefit, beyond biomarker expression, and how safety compares across dose levels.
- Manufacturing consistency, yield, capacity and cost, and whether a $60 million to $75 million facility investment is pursued.
- Actual restructuring costs and savings, and any material changes in litigation, licensing obligations or dilution from securities and warrants.